Epilepsy

This project is an international collaboration between clinical trial centres within the United States of America, Canada, Austria, Ireland and Australia and is overseen by The Epilepsy Study Consortium in the United States of America. The purpose of the project is to monitor the course of treatment for those who have recently been diagnosed with focal epilepsy. 

Trial phase 

check
Observational
Phase 1
Phase 2
Phase 3
Phase 4
Colitis and Crohn's Disease

In this study we aim to test the effects of a new drug, Apremilast, in order to find out if it can improve the symptoms of ulcerative colitis. Apremilast is taken orally and plays a role in reducing inflammatory reactions. Hence, it is believed Apremilast may have a role in the treatment of ulcerative colitis. The study will test two doses of Apremilast compared to placebo. The placebo is a “sugar pill” that contains no active drug but looks exactly like the study drug tablet. This study will test how well your body tolerates Apremilast and how well Apremilast treats the symptoms of your ulcerative colitis.

Trial phase 

check
Observational
Phase 1
Phase 2
Phase 3
Phase 4
Hepatitis

We are looking for hepatitis B patients to participate in a clinical trial to evaluate the safety and effectiveness of a new drug called ALN-HBV to treat chronic hepatitis B infection. Patients should be those who are currently receiving tenofovir or entecavir treatment for chronic hepatitis B virus (HBV) infection and do not have liver cirrhosis. 

Trial phase 

check
Observational
Phase 1
Phase 2
Phase 3
Phase 4
Epilepsy

This study is testing a new treatment for generalised epilepsy with uncontrolled primary generalised tonic-clonic (PGTC) seizures - sometimes also referred to as Grand-Mal seizures. The new treatment is called Lacosamide. This is a double-blind, randomized, placebo-controlled, parallel-group, multicentre study.

Trial phase 

check
Observational
Phase 1
Phase 2
Phase 3
Phase 4
Epilepsy

We are testing a new treatment for epilepsy where a drug to control your epilepsy will be administered through an infusion pump directly into the fluid surrounding the brain. 

Anticipated date that enrolment will close: June 2017

Trial phase 

check
Observational
Phase 1
Phase 2
Phase 3
Phase 4
Alzheimer's disease

Although the cause of Alzheimer’s disease is not yet clearly understood, it is believed that proteins in the brain, called beta-amyloid, are responsible. LY3202626 blocks a protein in the body called BACE1 that is responsible for the build-up of beta-amyloid. This study will look at whether the action of LY3202626 slows the progression of Alzheimer’s disease.

Trial phase 

check
Observational
Phase 1
Phase 2
Phase 3
Phase 4
Fabry disease

Researchers at The Royal Melbourne Hospital are investigating several new treatments to specifically treat Fabry disease, as well as additional studies to document and monitor the manifestations of disease beyond basic medical care.

Trial phase 

check
Observational
Phase 1
Phase 2
Phase 3
Phase 4
Alzheimer's disease

The purpose of this study is to test safety of a once-daily dose of CT1812 (the study drug) versus placebo given for 28 days in participants with mild to moderate Alzheimer’s disease.

Trial phase 

check
Observational
Phase 1
Phase 2
Phase 3
Phase 4